Javascript must be enabled to continue!
Abstract 741: CpG methylation abrogates KLF2-mediated transcriptional repression of telomerase in human T cells.
View through CrossRef
Abstract
Many genes in tumor cells are DNA-methylated and transcriptionally repressed. Constitutive expression of the limiting catalytic subunit of telomerase, hTERT, is one of the common signatures of tumor cells, even though its promoter is DNA-methylated. On the other hand, in normal somatic cells the promoter is unmethylated and transcription of hTERT is strictly regulated. In this study, we examined transcriptional regulation of the hTERT gene in normal and tumor cells. We identified a novel promoter element, which bound the zinc-finger transcription factor Krüpple-like factor 2 (KLF2) in normal human T Lymphocytes. The binding of KLF2 to the hTERT promoter element paralleled repression of hTERT transcription in resting normal T cells. T cell growth induced KLF2 release from the element and hTERT transcription. Forced reduction of KLF2 expression by siRNA in normal resting T cells increased the level of endogenous hTERT mRNA. The hTERT promoter is methylated in the KLF2-positive human T leukemic cell line, Kit 225, and KLF2-negative human T leukemic cell line, Jurkat. Treatment with the DNA methyltransferase inhibitor, Zebularine, reduced levels of CpG methylation in the hTERT promoter, resulting in downregulation of hTERT mRNA expression in KLF2-positive Kit 225 cells, while the Zebularine treatment did not cause any appreciable effects on hTERT expression in KLF2-negative Jurkat cells. Methylation of CpG sequences in endogenous and exogenous hTERT promoter elements inhibited the KLF2 binding to the element. Furthermore, KLF2 binding to the promoter is associated with histone H3 repressive marks, indicating KLF2-mediated epigenetic silencing of the hTERT promoter. Our results suggest that KLF2 partly controls strict transcriptional regulation of the hTERT gene through association and dissociation with the promoter in normal T cells, but in tumor cells these important interactions are prevented by DNA methylation.
Citation Format: Toshifumi Hara, Manami Yoshita, Masataka Nakamura. CpG methylation abrogates KLF2-mediated transcriptional repression of telomerase in human T cells. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 741. doi:10.1158/1538-7445.AM2013-741
American Association for Cancer Research (AACR)
Title: Abstract 741: CpG methylation abrogates KLF2-mediated transcriptional repression of telomerase in human T cells.
Description:
Abstract
Many genes in tumor cells are DNA-methylated and transcriptionally repressed.
Constitutive expression of the limiting catalytic subunit of telomerase, hTERT, is one of the common signatures of tumor cells, even though its promoter is DNA-methylated.
On the other hand, in normal somatic cells the promoter is unmethylated and transcription of hTERT is strictly regulated.
In this study, we examined transcriptional regulation of the hTERT gene in normal and tumor cells.
We identified a novel promoter element, which bound the zinc-finger transcription factor Krüpple-like factor 2 (KLF2) in normal human T Lymphocytes.
The binding of KLF2 to the hTERT promoter element paralleled repression of hTERT transcription in resting normal T cells.
T cell growth induced KLF2 release from the element and hTERT transcription.
Forced reduction of KLF2 expression by siRNA in normal resting T cells increased the level of endogenous hTERT mRNA.
The hTERT promoter is methylated in the KLF2-positive human T leukemic cell line, Kit 225, and KLF2-negative human T leukemic cell line, Jurkat.
Treatment with the DNA methyltransferase inhibitor, Zebularine, reduced levels of CpG methylation in the hTERT promoter, resulting in downregulation of hTERT mRNA expression in KLF2-positive Kit 225 cells, while the Zebularine treatment did not cause any appreciable effects on hTERT expression in KLF2-negative Jurkat cells.
Methylation of CpG sequences in endogenous and exogenous hTERT promoter elements inhibited the KLF2 binding to the element.
Furthermore, KLF2 binding to the promoter is associated with histone H3 repressive marks, indicating KLF2-mediated epigenetic silencing of the hTERT promoter.
Our results suggest that KLF2 partly controls strict transcriptional regulation of the hTERT gene through association and dissociation with the promoter in normal T cells, but in tumor cells these important interactions are prevented by DNA methylation.
Citation Format: Toshifumi Hara, Manami Yoshita, Masataka Nakamura.
CpG methylation abrogates KLF2-mediated transcriptional repression of telomerase in human T cells.
[abstract].
In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC.
Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 741.
doi:10.
1158/1538-7445.
AM2013-741.
Related Results
Telomerase activity in primary and secondary glioblastomas multiforme as a novel molecular tumor marker
Telomerase activity in primary and secondary glioblastomas multiforme as a novel molecular tumor marker
Object. Telomerase activity is responsible for cell immortality. To examine the role of telomerase in the carcinogenesis of human glioblastomas multiforme (GBMs), the authors studi...
Prediction model construction of mouse stem cell pluripotency using CpG and non-CpG DNA methylation markers
Prediction model construction of mouse stem cell pluripotency using CpG and non-CpG DNA methylation markers
AbstractBackgroundGenome-wide studies of DNA methylation across the epigenetic landscape provide insights into the heterogeneity of pluripotent embryonic stem cells (ESCs). Differe...
T Cell Modulation Combined with Intratumoral CpG Cures Lymphoma without the Need for Chemotherapy.
T Cell Modulation Combined with Intratumoral CpG Cures Lymphoma without the Need for Chemotherapy.
Abstract
Introduction: We have previously shown that intratumoral injection of CpG oligodeoxynucleotide plus systemic chemotherapy can induce T cell immunity against...
The Role of KLF2 in the Regulation of Atherosclerosis Development and Potential Use of KLF2-Targeted Therapy
The Role of KLF2 in the Regulation of Atherosclerosis Development and Potential Use of KLF2-Targeted Therapy
Kruppel like factor 2 (KLF2) is a mechanosensitive transcription factor participating in the regulation of vascular endothelial cells metabolism. Activating KLF2 in endothelial cel...
e0519 Rapamycin suppress KrÜppel-Like Factor 2 expression: mechanism of endothelial dysfunction associated with drug-eluting stents
e0519 Rapamycin suppress KrÜppel-Like Factor 2 expression: mechanism of endothelial dysfunction associated with drug-eluting stents
Objects
Although rapamycin released from drug-eluting stents (DESs) affect the antithrombogenic function of endothelial cells, the exactly mechanisms underlying t...
Liposome-Encapsulated CpG Oligodeoxynucleotides as a Potent Adjuvant for Inducing Type 1 Innate Immunity
Liposome-Encapsulated CpG Oligodeoxynucleotides as a Potent Adjuvant for Inducing Type 1 Innate Immunity
AbstractUnmethylated cytosine-phosphorothioate-guanine oligodeoxynucleotides (CpG-ODNs) exhibit potent immunostimulating activity by binding with Toll-like receptor 9 (TLR9) expres...
Expression of Telomerase Catalytic Component, Telomerase Reverse Transcriptase, in Human Gastric Carcinomas
Expression of Telomerase Catalytic Component, Telomerase Reverse Transcriptase, in Human Gastric Carcinomas
Telomerase activity is believed to be crucial for cellular immortality, which is considered to participate in the development of a majority of human cancers. Human telomerase rever...
Stable expression of promyelocytic leukaemia (PML) protein in telomerase positive MCF7 cells results in alternative lengthening of telomeres phenotype
Stable expression of promyelocytic leukaemia (PML) protein in telomerase positive MCF7 cells results in alternative lengthening of telomeres phenotype
Background
Cancer cells can employ telomerase or the alternative lengthening of telomeres (ALT) pathway for telomere maintenance. Cancer cells that use the ALT pathway exhibit dist...

